Transcription of INCLUDING PATIENT MEDICATION INFORMATION
{{id}} {{{paragraph}}}
Example: marketing
INCLUDING PATIENT MEDICATION INFORMATION
COPYRIGHT 2016-2020 ASTRAZENECA CANADA 1 of 56 PRODUCT MONOGRAPHINCLUDING PATIENT MEDICATION INFORMATIONTAGRISSO osimertinib tablets40 mg and 80 mg osimertinib as osimertinib mesylateEpidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AstraZeneca Canada Middlegate Road, Suite 5000 Mississauga, OntarioCanada, L4Y of Revision: November 26, 2020 Submission Control No:242157 TAGRISSO is a registered trademark of AstraZeneca AB, used under license by AstraZeneca 2016-2020 ASTRAZENECA CANADA 2 of 56 TABLE OF CONTENTSPRODUCT OF I: HEALTH PROFESSIONAL PRODUCT AND CLINICAL AND AND AND CLINICAL AND FORMS, COMPOSITION AND II: MEDICATION 2016-2020 ASTRAZENECA CANADA 3 of 56 TAGRISSO osimertinib tabletsPART I: HEALTH PROFESSIONAL INFORMATIONSUMMARY PRODUCT INFORMATIONR oute of AdministrationPharmaceuticalForm/Strengt hClinically Relevant Non-medici
other information relevant to the use of the drug. Patients should be advised to contact their healthcare provider immediately to report any new chest pain or discomfort, changes in
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
PRODUCT MONOGRAPH INCLUDING PATIENT, PRODUCT MONOGRAPH . INCLUDING PATIENT MEDICATION INFORMATION, PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION, INCLUDING PATIENT, INCLUDING PATIENT MEDICATION INFORMATION, PRODUCT MONOGRAPH. INCLUDING PATIENT MEDICATION INFORMATION, INCLUDING PATIENT MEDICATION, INFORMATION, Including